Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 5/2018

01-10-2018 | Case Report

Poorly differentiated ductal adenocarcinoma of the pancreas with rapid progression in a young man

Authors: Koji Tezuka, Tomoharu Ishiyama, Akiko Takeshita, Hidekazu Matsumoto, Akira Jingu, Jiro Kikuchi, Hideyuki Yamaya, Rintaro Ohe, Tetsuya Ishizawa

Published in: Clinical Journal of Gastroenterology | Issue 5/2018

Login to get access

Abstract

Pancreatic cancer in young adults is very rare. We report a case of young-onset poorly differentiated pancreatic ductal adenocarcinoma with rapid progression and poor prognosis in a 31-year-old Japanese man with no obvious family history of malignancy. Preoperative examinations revealed a mass lesion in the body of the pancreas, accompanied by a slightly dilated main pancreatic duct distal to the mass lesion. Pancreatic cancer with acute pancreatitis was suspected because of an elevation of serum pancreatic enzyme and tumor marker, along with imaging findings. Distal pancreatectomy with resection of the common hepatic artery and splenectomy along with lymph node dissection was performed. Microscopically, the tumor was mainly composed of poorly differentiated ductal adenocarcinoma. The postoperative course was uneventful, but the patient had multiple liver metastases 2 months postoperatively, in spite of adjuvant chemotherapy, and died 8 months postoperatively. This case may represent a rare instance of young-onset poorly differentiated ductal adenocarcinoma with rapid progression and may indicate potential risk factors of pancreatic cancer in young adults.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
2.
go back to reference Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission, posted to the SEER web site, 2016. http://seer.cancer.gov/csr/1975_2013/. Accessed 27 Mar 2017. Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission, posted to the SEER web site, 2016. http://​seer.​cancer.​gov/​csr/​1975_​2013/​. Accessed 27 Mar 2017.
3.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef
4.
go back to reference Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRef Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRef
5.
go back to reference Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRef Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRef
6.
go back to reference Lüttges J, Stigge C, Pacena M, Klöppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004;100:173–82.CrossRef Lüttges J, Stigge C, Pacena M, Klöppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004;100:173–82.CrossRef
7.
go back to reference Bergmann F, Aulmann S, Wente MN, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. 2006;59:580–4.CrossRef Bergmann F, Aulmann S, Wente MN, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. 2006;59:580–4.CrossRef
8.
go back to reference Eguchi H, Yamaue H, Unno M, et al. Clinicopathological characteristics of young patients with pancreatic cancer: an analysis of data from pancreatic cancer registry of Japan pancreas society. Pancreas. 2016;45:1411–7.CrossRef Eguchi H, Yamaue H, Unno M, et al. Clinicopathological characteristics of young patients with pancreatic cancer: an analysis of data from pancreatic cancer registry of Japan pancreas society. Pancreas. 2016;45:1411–7.CrossRef
9.
go back to reference Ohmoto A, Yachida S, Kubo E, et al. Clinicopathologic features and germline sequence variants in young patients (≤ 40 years old) with pancreatic ductal adenocarcinoma. Pancreas. 2016;45:1056–61.CrossRef Ohmoto A, Yachida S, Kubo E, et al. Clinicopathologic features and germline sequence variants in young patients (≤ 40 years old) with pancreatic ductal adenocarcinoma. Pancreas. 2016;45:1056–61.CrossRef
10.
go back to reference Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinoma in a young patient population—12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. 2009;100:8–12.CrossRef Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinoma in a young patient population—12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. 2009;100:8–12.CrossRef
11.
go back to reference Liszka L, Pająk J, Mrowiec S, et al. Precursor lesions of early onset pancreatic cancer. Virchows Arch. 2011;458:439–51.CrossRef Liszka L, Pająk J, Mrowiec S, et al. Precursor lesions of early onset pancreatic cancer. Virchows Arch. 2011;458:439–51.CrossRef
12.
go back to reference He J, Edil BH, Cameron JL, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17:339–44.CrossRef He J, Edil BH, Cameron JL, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17:339–44.CrossRef
13.
go back to reference McWilliams RR, Maisonneuve P, Bamlet WR, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case–control consortium (PanC4) analysis. Pancreas. 2016;45:311–6.CrossRef McWilliams RR, Maisonneuve P, Bamlet WR, et al. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case–control consortium (PanC4) analysis. Pancreas. 2016;45:311–6.CrossRef
14.
go back to reference Wang L, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2829–34.CrossRef Wang L, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2829–34.CrossRef
15.
go back to reference Beeghly-Fadiel A, Luu HN, Du L, et al. Early onset pancreatic malignancies: clinical characteristics and survival associations. Int J Cancer. 2016;139:2169–77.CrossRef Beeghly-Fadiel A, Luu HN, Du L, et al. Early onset pancreatic malignancies: clinical characteristics and survival associations. Int J Cancer. 2016;139:2169–77.CrossRef
16.
go back to reference Lin JC, Chan DC, Chen PJ, et al. Clinical characteristics of early onset pancreatic adenocarcinoma: a medical center experience and review of the literature. Pancreas. 2011;40:638–9.CrossRef Lin JC, Chan DC, Chen PJ, et al. Clinical characteristics of early onset pancreatic adenocarcinoma: a medical center experience and review of the literature. Pancreas. 2011;40:638–9.CrossRef
17.
go back to reference Tingstedt B, Weitkämper C, Andersson R. Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol. 2011;24:206–12.PubMedPubMedCentral Tingstedt B, Weitkämper C, Andersson R. Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol. 2011;24:206–12.PubMedPubMedCentral
18.
go back to reference Piciucchi M, Capurso G, Valente R, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–5.CrossRef Piciucchi M, Capurso G, Valente R, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–5.CrossRef
19.
go back to reference Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301:2553–62.CrossRef Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301:2553–62.CrossRef
20.
go back to reference Tsai MJ, Liao KS, Shih PM, et al. Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report. Kaohsiung J Med Sci. 2010;26:448–55.CrossRef Tsai MJ, Liao KS, Shih PM, et al. Relapsed acute pancreatitis as the initial presentation of pancreatic cancer in a young man: a case report. Kaohsiung J Med Sci. 2010;26:448–55.CrossRef
21.
go back to reference Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507.CrossRef Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507.CrossRef
22.
go back to reference Matsuo K, Ito H, Wakai K, et al. Cigarette smoking and pancreas cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol. 2011;41:1292–302.CrossRef Matsuo K, Ito H, Wakai K, et al. Cigarette smoking and pancreas cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol. 2011;41:1292–302.CrossRef
23.
go back to reference Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124:1292–9.CrossRef Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124:1292–9.CrossRef
24.
go back to reference Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169–70.CrossRef Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169–70.CrossRef
25.
go back to reference Raimondi S, Maisonneuve P, Löhr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomark Prev. 2007;16:1894–7.CrossRef Raimondi S, Maisonneuve P, Löhr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomark Prev. 2007;16:1894–7.CrossRef
26.
go back to reference Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.CrossRef Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.CrossRef
27.
go back to reference Chen J, Wu X, Huang Y, et al. Identification of genetic variants predictive of early onset pancreatic cancer through a population science analysis of functional genomic datasets. Oncotarget. 2016;7:56480–90.PubMedPubMedCentral Chen J, Wu X, Huang Y, et al. Identification of genetic variants predictive of early onset pancreatic cancer through a population science analysis of functional genomic datasets. Oncotarget. 2016;7:56480–90.PubMedPubMedCentral
28.
go back to reference Miyasaka K, Kawanami T, Shimokata H, et al. Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers in a Japanese male population. Pancreas. 2005;30:95–8.CrossRef Miyasaka K, Kawanami T, Shimokata H, et al. Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers in a Japanese male population. Pancreas. 2005;30:95–8.CrossRef
29.
go back to reference Talhout R, Schulz T, Florek E, et al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health. 2011;8:613–28.CrossRef Talhout R, Schulz T, Florek E, et al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health. 2011;8:613–28.CrossRef
30.
go back to reference Chen YC, Peng GS, Tsao TP, et al. Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics. 2009;19:588–99.CrossRef Chen YC, Peng GS, Tsao TP, et al. Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics. 2009;19:588–99.CrossRef
31.
go back to reference Trikudanathan G, Philip A, Dasanu CA, et al. Association between Helicobacter pylori infection and pancreatic cancer. a cumulative meta-analysis. JOP. 2011;12:26–31.PubMed Trikudanathan G, Philip A, Dasanu CA, et al. Association between Helicobacter pylori infection and pancreatic cancer. a cumulative meta-analysis. JOP. 2011;12:26–31.PubMed
32.
go back to reference Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62:1764–70.CrossRef Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62:1764–70.CrossRef
33.
go back to reference Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis. 2013;34:2193–7.CrossRef Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis. 2013;34:2193–7.CrossRef
34.
go back to reference Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010;70:1015–23.CrossRef Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010;70:1015–23.CrossRef
35.
go back to reference Sellam F, Harir N, Khaled MB, et al. Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults. J Gastrointest Oncol. 2015;6:505–10.PubMedPubMedCentral Sellam F, Harir N, Khaled MB, et al. Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults. J Gastrointest Oncol. 2015;6:505–10.PubMedPubMedCentral
36.
go back to reference Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRef Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRef
37.
go back to reference Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma—a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106.CrossRef Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma—a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106.CrossRef
38.
go back to reference Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.CrossRef Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.CrossRef
39.
go back to reference Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14:3527–33.CrossRef Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14:3527–33.CrossRef
40.
go back to reference Lahat G, Lubezky N, Loewenstein S, et al. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Ann Surg Oncol. 2014;21:S750–7.CrossRef Lahat G, Lubezky N, Loewenstein S, et al. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Ann Surg Oncol. 2014;21:S750–7.CrossRef
41.
go back to reference Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629–37.CrossRef Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629–37.CrossRef
42.
go back to reference Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–83.CrossRef Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–83.CrossRef
43.
go back to reference Tada M, Kawabe T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265–70.CrossRef Tada M, Kawabe T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265–70.CrossRef
44.
go back to reference Bang UC, Benfield T, Hyldstrup L, et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology. 2014;146:989–94.CrossRef Bang UC, Benfield T, Hyldstrup L, et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology. 2014;146:989–94.CrossRef
45.
go back to reference Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20:3794–801.CrossRef Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20:3794–801.CrossRef
Metadata
Title
Poorly differentiated ductal adenocarcinoma of the pancreas with rapid progression in a young man
Authors
Koji Tezuka
Tomoharu Ishiyama
Akiko Takeshita
Hidekazu Matsumoto
Akira Jingu
Jiro Kikuchi
Hideyuki Yamaya
Rintaro Ohe
Tetsuya Ishizawa
Publication date
01-10-2018
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 5/2018
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0859-z

Other articles of this Issue 5/2018

Clinical Journal of Gastroenterology 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.